SNCA and Parkinson disease: Sampson et al. (2016) revealed that FMT from PD patients into genetically susceptible ASO (alpha-synuclein-overexpressing) mice, a mouse model of PD, enhanced motor impairment compared to mice that received FMT from healthy donors.